Physiomics (GB:PYC) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Physiomics plc, a leader in mathematical modelling, has secured a £157k contract with a major pharmaceutical client to enhance dosing and scheduling decisions for a novel cancer therapy. This project marks the company’s first use of Antibody-Drug Conjugates in their Virtual Tumour platform, positioning Physiomics at the cutting edge of oncology drug development. The collaboration underscores the ongoing trust in Physiomics’ expertise in advanced therapeutic modelling.
For further insights into GB:PYC stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue